Role of induction and consolidation chemotherapy in elderly acute myeloid leukemia patients
详细信息 查看全文
- 作者：Soo-Jeong Kim (1)
June-Won Cheong (1)
Dae-Young Kim (2)
Je-Hwan Lee (2)
Kyoo-Hyung Lee (2)
Yeo-Kyeoung Kim (3)
Hyeong-Joon Kim (3)
Ik-Chan Song (4)
Deog-Yeon Jo (4)
Jeong-Ok Lee (5)
Soo-Mee Bang (5)
Jinny Park (6)
Jae Hoon Lee (6)
Won-Sik Lee (7)
Young-Don Joo (7)
Chi Hoon Maeng (8)
Hwi-Joong Yoon (8)
Na-Ri Lee (9)
Jae-Yong Kwak (9)
Kyoung Ha Kim (10)
Jong-Ho Won (10)
Bo Ram Han (11)
Dae Young Zang (11)
Joon Ho Moon (12)
Sang Kyun Sohn (12)
Sung Hwa Bae (13)
Hun Mo Ryoo (13)
Sung-Yong Kim (14)
Mark Hong Lee (14)
Yoo Hong Min (1) - 关键词：Elderly AML ; Induction ; Consolidation
- 刊名：International Journal of Hematology
- 出版年：2014
- 出版时间：August 2014
- 年：2014
- 卷：100
- 期：2
- 页码：141-151
- 全文大小：516 KB
- 参考文献：1. SEER. Cancer statistics review 1975-007. 2010.
2. Juliusson G, Antunovic P, Derolf A, Lehmann S, M?llg?rd L, Stockelberg D, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113:4179-7. CrossRef
3. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98:1312-0. CrossRef
4. Wilson CS, Davidson GS, Martin SB, Andries E, Potter J, Harvey R, et al. Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction. Blood. 2006;108:685-6. CrossRef
5. Leith CP, Kopecky KJ, Chen IM, Eijdems L, Slovak ML, McConnell TS, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood. 1999;94:1086-9.
6. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, et al. Age and acute myeloid leukemia. Blood. 2006;107:3481-. CrossRef
7. L?wenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361:1235-8. CrossRef
8. Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica. 2012;97:1916-4. CrossRef
9. Dombret H, Chastang C, Fenaux P, Reiffers J, Bordessoule D, Bouabdallah R, et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. N Engl J Med. 1995;332:1678-3. CrossRef
10. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman P, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med. 1995;332:1671-. CrossRef
11. Malfuson JV, Etienne A, Turlure P, de Revel T, Thomas X, Contentin N, et al. Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia. Haematologica. 2008;93:1806-3. CrossRef
12. Wheatley K, Brookes CL, Howman AJ, Goldstone AH, Milligan DW, Prentice AG, et al. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br J Haematol. 2009;145:598-05. CrossRef
13. Kantarjian H, O’Brien S, Cortes J, Giles F, Faderl S, Jabbour E, et al. Results of intensive chemotherapy in 998 patients age 65?years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006;106:1090-. CrossRef
14. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96:4075-3.
15. Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21:4642-. CrossRef
16. L?wenberg B, Zittoun R, Kerkhofs H, Jehn U, Abels J, Debusscher L, et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65?+?years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol. 1989;7:1268-4.
17. Baz R, Rodriguez C, Fu AZ, Jawde RA, Kalaycio M, Advani A, et al. Impact of remission induction chemotherapy on survival in older adults with acute myeloid leukemia. Cancer. 2007;110:1752-. CrossRef
18. Pulsoni A, Pagano L, Latagliata R, Casini M, Cerri R, Crugnola M, et al. Survival of elderly patients with acute myeloid leukemia. Haematologica. 2004;89:296-02.
19. Roboz GJ, Wissa U, Ritchie EK, Gergis U, Mayer S, Scandura JM, et al. Are low-intensity induction strategies better for older patients with acute myeloid leukemia? Leuk Res. 2012;36:407-2. CrossRef
20. Kantarjian H, Ravandi F, O’Brien S, Cortes J, Faderl S, Garcia Manero G, et al. Intensive chemotherapy does not benefit most older patients (age 70?years or older) with acute myeloid leukemia. Blood. 2010;116:4422-. CrossRef
21. Tsimberidou AM, Kantarjian HM, Wen S, O’Brien S, Cortes J, Wierda WG, et al. The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients. Clin Cancer Res. 2008;14:721-0. CrossRef
22. Gupta V, Chun K, Yi QL, Minden M, Schuh A, Wells R, et al. Disease biology rather than age is the most important determinant of survival of patients?>?or?=?60?years with acute myeloid leukemia treated with uniform intensive therapy. Cancer. 2005;103:2082-0. CrossRef
23. Rollig C, Thiede C, Gramatzki M, Aulitzky W, Bodenstein H, Bornhauser M, et al. A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. Blood. 2010;116:971-. CrossRef
24. Koren Michowitz M, Sato Otsubo A, Nagler A, Haferlach T, Ogawa S, Koeffler HP. Older patients with normal karyotype acute myeloid leukemia have a higher rate of genomic changes compared to young patients as determined by SNP array analysis. Leuk Res. 2012;36:467-3. CrossRef
25. Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98:1302-1. CrossRef
26. Burnett AK, Hills RK, Milligan DW, Goldstone AH, Prentice AG, McMullin MF, et al. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. J Clin Oncol. 2010;28:586-5. CrossRef - 作者单位：Soo-Jeong Kim (1)
June-Won Cheong (1)
Dae-Young Kim (2)
Je-Hwan Lee (2)
Kyoo-Hyung Lee (2)
Yeo-Kyeoung Kim (3)
Hyeong-Joon Kim (3)
Ik-Chan Song (4)
Deog-Yeon Jo (4)
Jeong-Ok Lee (5)
Soo-Mee Bang (5)
Jinny Park (6)
Jae Hoon Lee (6)
Won-Sik Lee (7)
Young-Don Joo (7)
Chi Hoon Maeng (8)
Hwi-Joong Yoon (8)
Na-Ri Lee (9)
Jae-Yong Kwak (9)
Kyoung Ha Kim (10)
Jong-Ho Won (10)
Bo Ram Han (11)
Dae Young Zang (11)
Joon Ho Moon (12)
Sang Kyun Sohn (12)
Sung Hwa Bae (13)
Hun Mo Ryoo (13)
Sung-Yong Kim (14)
Mark Hong Lee (14)
Yoo Hong Min (1)
1. Division of Hematology, Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, 50 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, Republic of Korea
2. Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
3. Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Jeollanam-do, Republic of Korea
4. Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Republic of Korea
5. Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
6. Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Hospital, Incheon, Republic of Korea
7. Department of Hemato/Oncology, College of Medicine, Inje University, Busan, Republic of Korea
8. Department of Hematology-Oncology, College of Medicine, Kyung Hee University Seoul, Seoul, Republic of Korea
9. Department of Internal Medicine, Chonbuk National University Medical School, Jeonju, Republic of Korea
10. Division of Hematology-Oncology, Department of Internal Medicine, Soonchunhyang University College of Medicine, Seoul, Korea
11. Division of Hematology-Oncology, Hallym University Medical Center, Hallym University College of Medicine, Seoul, Republic of Korea
12. Department of Hematology and Medical Oncology, Kyungpook National University Hospital, Daegu, Republic of Korea
13. Department of Hematology-Oncology, Deagu Catholic Medical Center, Catholic University of Daegu School of Medicine, Deagu, Korea
14. Division of Hematology-Oncology, Department of Internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Republic of Korea - ISSN：1865-3774
文摘
The present study sought to elucidate the role of induction and consolidation therapy in elderly patients. We retrospectively collected data of 477 patients who were aged over 60?years at the time of acute myeloid leukemia (AML) diagnosis. The median overall survival (OS) was 339?days in the induction group (n?=?266) and 86?days in the best supportive care group (n?=?211) (P?P?=?0.002]. Mortality correlated with failure to achieve CR (HR 4.059; P?2) (HR 2.731; P?=?0.035). In CR patients, poor karyotype and absence of consolidation (HR 2.313; P?=?0.003) correlated with mortality. More than one cycle of consolidation was associated with better OS (P?P?=?0.005). Intensive induction in patients with good performance and >1 cycle of consolidation after CR may be the best strategy for improving OS in elderly AML patients.